Absentia Labs
Boston
About Absentia Labs
Absentia Labs is a next-generation drug discovery platform using in-silico whole-organism models to replace traditional animal testing. With over 92% of animal models failing to translate to humans, our physics-AI model offers a more accurate, ethical, and cost-effective solution. We have already created cell differentiation, reprogramming, drug absorption, tissue regeneration, and embryonic development in mice, and plan to scale our model and expand to other model organisms to reach its full potential. Our product will provide a cheaper, faster and more ethical alternative for preclinical drug development, accelerating the drug discovery process while improving success rates
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Pre-Seed (Aug 2025)
- Website: absentia.bio
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Intelligent Systems, Life Science
Canonical: https://fsome.com/organization/absentia-labs-184250 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.